FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2056489696> ?p ?o ?g. }

• W2056489696 endingPage "235" @default.
• W2056489696 startingPage "228" @default.
• W2056489696 abstract "According to the overview of Early Breast Cancer Trialists' Collaborative Group, anthracycline containing regimens are superior to cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) as adjuvant chemotherapy for breast carcinoma, but no comparative information is available in terms of primary chemotherapy. In the current randomized controlled trial, the authors compared CMF with a chemotherapy regimen including CMF, epirubicin, and vincristine (CMFEV).Two hundred eleven patients with Stages I and II palpable breast carcinoma and tumor diameter > 2.5 cm or < or = 2.5 cm with cytologically proven axillary lymph node involvement were randomized to receive CMF (arm A) or CMFEV regimen (arm B) for four cycles before surgery. After surgery, patients in both arms received adjuvant CMF for three cycles; the postmenopausal patients also received tamoxifen for two years.There were no significant differences in the complete response (CR) and in the CR plus partial response (PR) rates between the two arms. In the subset analysis, among premenopausal patients, significantly higher rates of CR (26% vs 4%, P = 0.004) and of CR + PR rates (80% vs 54%, P = 0.007) were observed in the CMFEV, as compared to the CMF arm. Multivariate analysis confirmed the presence of a significant interaction between menopausal status and type of treatment on the probability of achieving CR (P = 0.02) or CR + PR (P = 0.01). There were no major differences in the side effects of the two treatments, with the exception of more frequent alopecia in the experimental arm.The results of the current study are in line with those of previous published randomized clinical trials comparing regimens without and with anthracycline as adjuvant treatment, indicating an agreement between the short term response to primary chemotherapy and the long term results observed in the adjuvant setting." @default.
• W2056489696 created "2016-06-24" @default.
• W2056489696 creator A5002069319 @default.
• W2056489696 creator A5012141269 @default.
• W2056489696 creator A5026665975 @default.
• W2056489696 creator A5027643126 @default.
• W2056489696 creator A5038784620 @default.
• W2056489696 creator A5048969389 @default.
• W2056489696 creator A5052225949 @default.
• W2056489696 creator A5060297610 @default.
• W2056489696 creator A5066793236 @default.
• W2056489696 creator A5084853846 @default.
• W2056489696 creator A5085930224 @default.
• W2056489696 date "2002-07-11" @default.
• W2056489696 modified "2023-09-25" @default.
• W2056489696 title "Randomized trial comparing cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) with rotational CMF, epirubicin and vincristine as primary chemotherapy in operable breast carcinoma" @default.
• W2056489696 cites W1262485082 @default.
• W2056489696 cites W1524417847 @default.
• W2056489696 cites W1566526521 @default.
• W2056489696 cites W1848579801 @default.
• W2056489696 cites W1861752845 @default.
• W2056489696 cites W1876276942 @default.
• W2056489696 cites W1882532563 @default.
• W2056489696 cites W1929485622 @default.
• W2056489696 cites W1933080611 @default.
• W2056489696 cites W1974513579 @default.
• W2056489696 cites W1997249116 @default.
• W2056489696 cites W1999306826 @default.
• W2056489696 cites W2086945638 @default.
• W2056489696 cites W2130920434 @default.
• W2056489696 cites W2139510434 @default.
• W2056489696 cites W2167805334 @default.
• W2056489696 cites W2214029008 @default.
• W2056489696 cites W2226691778 @default.
• W2056489696 cites W2254049575 @default.
• W2056489696 cites W2271771009 @default.
• W2056489696 cites W2336241765 @default.
• W2056489696 cites W2339454025 @default.
• W2056489696 cites W35843882 @default.
• W2056489696 cites W2772783302 @default.
• W2056489696 doi "https://doi.org/10.1002/cncr.10678" @default.
• W2056489696 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12124820" @default.
• W2056489696 hasPublicationYear "2002" @default.
• W2056489696 type Work @default.
• W2056489696 sameAs 2056489696 @default.
• W2056489696 citedByCount "9" @default.
• W2056489696 countsByYear W20564896962021 @default.
• W2056489696 crossrefType "journal-article" @default.
• W2056489696 hasAuthorship W2056489696A5002069319 @default.
• W2056489696 hasAuthorship W2056489696A5012141269 @default.
• W2056489696 hasAuthorship W2056489696A5026665975 @default.
• W2056489696 hasAuthorship W2056489696A5027643126 @default.
• W2056489696 hasAuthorship W2056489696A5038784620 @default.
• W2056489696 hasAuthorship W2056489696A5048969389 @default.
• W2056489696 hasAuthorship W2056489696A5052225949 @default.
• W2056489696 hasAuthorship W2056489696A5060297610 @default.
• W2056489696 hasAuthorship W2056489696A5066793236 @default.
• W2056489696 hasAuthorship W2056489696A5084853846 @default.
• W2056489696 hasAuthorship W2056489696A5085930224 @default.
• W2056489696 hasBestOaLocation W20564896962 @default.
• W2056489696 hasConcept C121608353 @default.
• W2056489696 hasConcept C126322002 @default.
• W2056489696 hasConcept C141071460 @default.
• W2056489696 hasConcept C143998085 @default.
• W2056489696 hasConcept C168563851 @default.
• W2056489696 hasConcept C2776694085 @default.
• W2056489696 hasConcept C2776755627 @default.
• W2056489696 hasConcept C2776802502 @default.
• W2056489696 hasConcept C2777176818 @default.
• W2056489696 hasConcept C2779429289 @default.
• W2056489696 hasConcept C2780456651 @default.
• W2056489696 hasConcept C2780835546 @default.
• W2056489696 hasConcept C2781413609 @default.
• W2056489696 hasConcept C3018521938 @default.
• W2056489696 hasConcept C530470458 @default.
• W2056489696 hasConcept C71924100 @default.
• W2056489696 hasConceptScore W2056489696C121608353 @default.
• W2056489696 hasConceptScore W2056489696C126322002 @default.
• W2056489696 hasConceptScore W2056489696C141071460 @default.
• W2056489696 hasConceptScore W2056489696C143998085 @default.
• W2056489696 hasConceptScore W2056489696C168563851 @default.
• W2056489696 hasConceptScore W2056489696C2776694085 @default.
• W2056489696 hasConceptScore W2056489696C2776755627 @default.
• W2056489696 hasConceptScore W2056489696C2776802502 @default.
• W2056489696 hasConceptScore W2056489696C2777176818 @default.
• W2056489696 hasConceptScore W2056489696C2779429289 @default.
• W2056489696 hasConceptScore W2056489696C2780456651 @default.
• W2056489696 hasConceptScore W2056489696C2780835546 @default.
• W2056489696 hasConceptScore W2056489696C2781413609 @default.
• W2056489696 hasConceptScore W2056489696C3018521938 @default.
• W2056489696 hasConceptScore W2056489696C530470458 @default.
• W2056489696 hasConceptScore W2056489696C71924100 @default.
• W2056489696 hasIssue "2" @default.
• W2056489696 hasLocation W20564896961 @default.
• W2056489696 hasLocation W20564896962 @default.
• W2056489696 hasLocation W20564896963 @default.
• W2056489696 hasOpenAccess W2056489696 @default.
• W2056489696 hasPrimaryLocation W20564896961 @default.

• next